Last reviewed · How we verify
Bi-PegLyte
Bi-PegLyte is a Bowel preparation agent / Laxative combination Small molecule drug developed by University of Manitoba. It is currently FDA-approved for Bowel cleansing prior to colonoscopy or other colorectal procedures.
Bi-PegLyte is a bowel preparation agent that combines bisacodyl and polyethylene glycol to cleanse the colon by osmotic laxation and stimulant action.
Bi-PegLyte is a bowel preparation agent that combines bisacodyl and polyethylene glycol to cleanse the colon by osmotic laxation and stimulant action. Used for Bowel cleansing prior to colonoscopy or other colorectal procedures.
At a glance
| Generic name | Bi-PegLyte |
|---|---|
| Sponsor | University of Manitoba |
| Drug class | Bowel preparation agent / Laxative combination |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
The polyethylene glycol (PEG) component works as an osmotic laxative, drawing water into the intestinal lumen to soften stool and promote bowel evacuation. Bisacodyl is a stimulant laxative that increases intestinal motility and secretion. Together, these agents provide effective colonic cleansing prior to diagnostic or therapeutic procedures.
Approved indications
- Bowel cleansing prior to colonoscopy or other colorectal procedures
Common side effects
- Nausea
- Abdominal cramping
- Bloating
- Vomiting
Key clinical trials
- Bowel Preparation for Colonoscopy Among Individuals With Crohn's and Ulcerative Colitis Disease. (PHASE4)
- Prospective Trial Of Osmolar Protocol Solution on Colonoscopy Outcomes and Patient Experience (NA)
- The Bowel CLEAnsing: A National Initiative (PHASE4)
- 2L Oral Bi-PegLyte Versus 2L Oral MoviPrep Regimen for Outpatient Colonic Preparation (PHASE4)
- Comparing 2L Bi-Pegyte to 4L PegLyte Regiments for Outpatient Colonic Preparation (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bi-PegLyte CI brief — competitive landscape report
- Bi-PegLyte updates RSS · CI watch RSS
- University of Manitoba portfolio CI
Frequently asked questions about Bi-PegLyte
What is Bi-PegLyte?
How does Bi-PegLyte work?
What is Bi-PegLyte used for?
Who makes Bi-PegLyte?
What drug class is Bi-PegLyte in?
What development phase is Bi-PegLyte in?
What are the side effects of Bi-PegLyte?
Related
- Drug class: All Bowel preparation agent / Laxative combination drugs
- Manufacturer: University of Manitoba — full pipeline
- Therapeutic area: All drugs in Gastroenterology
- Indication: Drugs for Bowel cleansing prior to colonoscopy or other colorectal procedures
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing